<p>Paper on Role of MOSPD2 in Metastatic Breast Cancer Published in International Journal of Cancer TEL AVIV, Israel , July 10, 2018 (GLOBE NEWSWIRE) --   VBL Therapeutics  (NASDAQ:VBLT) today announced the publication of data on the potential role of MOSPD2 in metastatic breast cancer in the</p> ...

<p>TEL AVIV, Israel , June 27, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics  (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer,  today announced the closing of its previously announced registered</p>...

<p>TEL AVIV, Israel , June 26, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics  (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer,  today announced that it has entered into definitive agreements with</p...

<p>TEL AVIV, Israel , June 05, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics  (NASDAQ:VBLT) today presented data on its novel MOSPD2 program in oncology and inflammation at the 2018 BIO International Convention in Boston, Massachusetts . &quot;Our research has shown that MOSPD2 plays a key role in the</...

<p>TEL AVIV, Israel , May 24, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that the Company will present an update on the OVAL Phase...

<p>Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel , May 17, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced<...

<p>TEL AVIV, Israel , May 07, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will present data on its novel MOSPD2 program at<...

<p>TEL AVIV, Israel , May 01, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcas...

<p>TEL AVIV, Israel , April 16, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today presented a late-breaking study demonstrating a novel bi-specific antibody that induces immune-cell mediated killing of cancer cells through binding to a tumor membrane receptor, MOSPD2.</p> ...

<p>TEL AVIV, Israel , April 10, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that the Company will present new data on MOSPD2, a nov...